Skip to content
‹ Back to IndustriesSciences

Supply Side West: Sleep Deprivation Solutions Are Not One-Size-Fits-All

Dr. Susan Hewlings joined MarketScale from Supply Side West to talk about a taking a more holistic view of sleep. “The important thing to understand…is the fact that sleep is way more complex than how many hours you slept,” said Hewlings. She advocates for evaluating a number of factors that contribute to poor sleep and…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Susan Hewlings VideoTyler Kern Video
Share

Key takeaways

01

Susan Hewlings joined MarketScale from Supply Side West to talk about a taking a more holistic view of sleep.

02

“The important thing to understand…is the fact that sleep is way more complex than how many hours you slept,” said Hewlings.

03

She advocates for evaluating a number of factors that contribute to poor sleep and…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI in a free MarketScale workspace. Qualifying companies also get one professional video edit a month. No credit card.

Start free

Dr. Susan Hewlings joined MarketScale from Supply Side West to talk about a taking a more holistic view of sleep.

“The important thing to understand…is the fact that sleep is way more complex than how many hours you slept,” said Hewlings. She advocates for evaluating a number of factors that contribute to poor sleep and tacking those issues individually, rather than taking a one-size-fits-all approach.

“There’s different mechanisms of actions that you have to consider when you’re considering what products to either develop or take if you’re a consumer.”

Dr. Hewlings also made the argument that sleep deprivation is something that should be top of mind for businesses due to the money that is lost due to a lack of productivity.

Dr. Susan Hewlings is the Director of Scientific Affairs at Nutrasource in addition to being the Co-Founder and Science Director at Substantiation Sciences.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0. No credit card. Company confirmation required.

More Sciences Insights

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

CDMOs’ new capacity skews stainless by liters, but single-use leads by system count

Contract Pharma reports bioTRAK data projecting CDMOs will install roughly 120 bioreactors by 2030. It says 71% of added volume is large-scale stainless steel, while 61% of systems are single-use.

  • 01Utilization discipline is still driving builds: BioTRAK’s Dawn Ecker told Contract Pharma expansion conversations typically start after a site is booked above ~80% for several years.

Sep 22, 2026

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512